XTLB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2016Q4

0.000

-100%

Estimates Revision

Stock Price

Go Down

-51.89%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for X T L Biopharmaceuticals Ltd (XTLB.O) is 1.20, compared to its 5-year average forward P/E of 5.94. For a more detailed relative valuation and DCF analysis to assess X T L Biopharmaceuticals Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

5.94

Current PE

1.20

Overvalued PE

10.66

Undervalued PE

1.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

0.06

Current PS

0.02

Overvalued PS

0.10

Undervalued PS

0.01

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

XTLB News & Events

Events Timeline

No data

News

4.5

01-02Benzinga

Baidu Inc Proposes Spinoff of Kunlunxin H Shares, Stock Rises 12.3%

7.0

2025-12-26Newsfilter

XTL Biopharmaceuticals Faces Nasdaq Delisting Risk, Must Regain Compliance in 180 Days

7.0

2025-12-24Globenewswire

XTL Biopharmaceuticals Fails to Meet Nasdaq Minimum Bid Price Requirement

People Also Watch

Frequently Asked Questions

What is X T L Biopharmaceuticals Ltd (XTLB) stock price today?

The current price of XTLB is 0.6736 USD — it has decreased -2.46 % in the last trading day.

What is X T L Biopharmaceuticals Ltd (XTLB)'s business?

X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

What is the price predicton of XTLB Stock?

Wall Street analysts forecast XTLB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XTLB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is X T L Biopharmaceuticals Ltd (XTLB)'s revenue for the last quarter?

X T L Biopharmaceuticals Ltd revenue for the last quarter amounts to 289.00K USD, decreased % YoY.

What is X T L Biopharmaceuticals Ltd (XTLB)'s earnings per share (EPS) for the last quarter?

X T L Biopharmaceuticals Ltd. EPS for the last quarter amounts to -0.00 USD, decreased % YoY.

What changes have occurred in the market's expectations for X T L Biopharmaceuticals Ltd (XTLB)'s fundamentals?

The market is revising No Change the revenue expectations for XTLB for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -51.89%.

How many employees does X T L Biopharmaceuticals Ltd (XTLB). have?

X T L Biopharmaceuticals Ltd (XTLB) has 4 emplpoyees as of January 11 2026.

What is X T L Biopharmaceuticals Ltd (XTLB) market cap?

Today XTLB has the market capitalization of 5.94M USD.